CN1874766A - 神经激肽拮抗剂在尿失禁治疗中的用途 - Google Patents

神经激肽拮抗剂在尿失禁治疗中的用途 Download PDF

Info

Publication number
CN1874766A
CN1874766A CNA2004800316761A CN200480031676A CN1874766A CN 1874766 A CN1874766 A CN 1874766A CN A2004800316761 A CNA2004800316761 A CN A2004800316761A CN 200480031676 A CN200480031676 A CN 200480031676A CN 1874766 A CN1874766 A CN 1874766A
Authority
CN
China
Prior art keywords
phenyl
hydrogen
methyl
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800316761A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·格鲁
K·H·麦卡利斯特
E·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1874766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1874766A publication Critical patent/CN1874766A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2004800316761A 2003-10-27 2004-10-26 神经激肽拮抗剂在尿失禁治疗中的用途 Pending CN1874766A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51479103P 2003-10-27 2003-10-27
US60/514,791 2003-10-27

Publications (1)

Publication Number Publication Date
CN1874766A true CN1874766A (zh) 2006-12-06

Family

ID=34520229

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800316761A Pending CN1874766A (zh) 2003-10-27 2004-10-26 神经激肽拮抗剂在尿失禁治疗中的用途

Country Status (9)

Country Link
US (1) US7776851B2 (enExample)
EP (2) EP1686985A2 (enExample)
JP (1) JP2007509184A (enExample)
CN (1) CN1874766A (enExample)
AU (1) AU2004283038B9 (enExample)
BR (1) BRPI0415923A (enExample)
CA (1) CA2543552A1 (enExample)
MX (1) MXPA06004688A (enExample)
WO (1) WO2005039563A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6664253B2 (en) * 2000-10-17 2003-12-16 Boehringer Ingelheim Pharma Kg Neurokinin antagonists
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
US7335776B2 (en) * 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient
KR100887471B1 (ko) * 2002-01-18 2009-03-10 교린 세이야꾸 가부시키 가이샤 축합 바이사이클릭 피리미딘 유도체
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
US7026309B2 (en) * 2002-03-26 2006-04-11 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
CN1330654C (zh) * 2002-03-26 2007-08-08 杏林制药株式会社 稠合双环嘧啶衍生物

Also Published As

Publication number Publication date
AU2004283038B9 (en) 2008-04-24
US20070149504A1 (en) 2007-06-28
JP2007509184A (ja) 2007-04-12
WO2005039563A3 (en) 2005-06-30
WO2005039563A2 (en) 2005-05-06
EP1686985A2 (en) 2006-08-09
US7776851B2 (en) 2010-08-17
AU2004283038B2 (en) 2008-01-31
BRPI0415923A (pt) 2006-12-26
CA2543552A1 (en) 2005-05-06
EP2158910A1 (en) 2010-03-03
MXPA06004688A (es) 2006-07-05
AU2004283038A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CN1726022A (zh) 用于治疗纤维肌痛及其相关疾病的普加巴林及其衍生物
CN1498104A (zh) 肽类化合物用于治疗异常性疼痛或其他不同类慢性痛或幻痛的新应用
US20040235922A1 (en) Compositions and methods for inducing adipose tissue cell death
CN1738611A (zh) 用作抗偏头痛剂的α－氨基酰胺衍生物
US6562858B2 (en) Method for treating depression
JP6116679B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
JP2013518894A (ja) ５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト
CN100346831C (zh) Pde抑制剂与白三烯受体拮抗剂的并用药物
US6239162B1 (en) Method for treating depression
CN101076328A (zh) 用于睡眠障碍的预防或治疗剂
CN1842328A (zh) 可用作抗炎剂的α－氨基酰胺衍生物
CN1301714C (zh) 酰氨基亚链烯基酰胺衍生物在功能性内脏能动性疾病中的应用
CN1040505C (zh) 制备抗高血压的复合制剂的方法
JP2007509184A (ja) 尿失禁の処置におけるニューロキニンアンタゴニストの使用
CN1708294A (zh) Cdk抑制剂和米托蒽醌的联合
JPWO2004030674A1 (ja) プロスタグランジンｄ▲下２▼、プロスタグランジンｄ▲下２▼アゴニストおよびプロスタグランジンｄ▲下２▼アンタゴニストの新規用途
CN1761467A (zh) 2－取代－吡啶－甲胺衍生物在制备用于治疗神经性和心理性慢性疼痛症状的药物的用途
HK1081875A (en) Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CN1649576A (zh) 用于治疗癌症疼痛的方法和组合物
FR2890862A1 (fr) Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
TW200418488A (en) Organic compounds
NZ718978A (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
HK1073795A (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
ZA200401223B (en) Substituted 4-aminocyclohexanol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20061206